AR122731A1 - Oligonucleótidos mejorados para modular la expresión de fubp1 - Google Patents

Oligonucleótidos mejorados para modular la expresión de fubp1

Info

Publication number
AR122731A1
AR122731A1 ARP210101742A ARP210101742A AR122731A1 AR 122731 A1 AR122731 A1 AR 122731A1 AR P210101742 A ARP210101742 A AR P210101742A AR P210101742 A ARP210101742 A AR P210101742A AR 122731 A1 AR122731 A1 AR 122731A1
Authority
AR
Argentina
Prior art keywords
fubp1
treatment
antisense oligonucleotides
relates
conjugates
Prior art date
Application number
ARP210101742A
Other languages
English (en)
Inventor
Sabine Sewing
Sren Ottosen
Jacob Ravn
Lykke Pedersen
Souphalone Luangsay
Erich Koller
Johanna Marie Walther
Helene Maria Gylling
Natascha Hruschka
Susanne Mohr
Valentina Darienzo
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR122731A1 publication Critical patent/AR122731A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Abstract

La presente invención se refiere a oligonucleótidos antisentido mejorados que son complementarios de la proteína de unión al elemento en dirección 5’ lejano 1 (FUBP1) y son capaces de reducir un ácido nucleico diana de FUBP1, tal como mARN de FUBP1. La invención se refiere a oligonucleótidos antisentido mejorados que actúan sobre FUBP1 o conjugados de estos para su uso en el tratamiento y/o prevención de una infección por el virus de la hepatitis B (HBV), en particular, una infección por HBV crónica. La invención se refiere, en particular, al uso de los oligonucleótidos antisentido mejorados que actúan sobre FUBP1 o conjugados de estos para desestabilizar cccADN, tal como cccADN de HBV. La invención también se refiere a oligonucleótidos antisentido mejorados que actúan sobre FUBP1 o conjugados de estos para su uso en el tratamiento del cáncer. La presente invención también comprende una composición farmacéutica y su uso en el tratamiento y/o prevención de una infección por HBV, o su uso en el tratamiento del cáncer.
ARP210101742A 2020-06-26 2021-06-24 Oligonucleótidos mejorados para modular la expresión de fubp1 AR122731A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20182437 2020-06-26

Publications (1)

Publication Number Publication Date
AR122731A1 true AR122731A1 (es) 2022-10-05

Family

ID=71170391

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101742A AR122731A1 (es) 2020-06-26 2021-06-24 Oligonucleótidos mejorados para modular la expresión de fubp1

Country Status (16)

Country Link
US (1) US20220031730A1 (es)
EP (1) EP4171575A1 (es)
JP (1) JP2023531249A (es)
KR (1) KR20230028475A (es)
CN (1) CN116033908A (es)
AR (1) AR122731A1 (es)
AU (1) AU2021295609A1 (es)
BR (1) BR112022026612A2 (es)
CA (1) CA3186722A1 (es)
CO (1) CO2023000116A2 (es)
CR (1) CR20220645A (es)
IL (1) IL299269A (es)
MX (1) MX2022016280A (es)
PE (1) PE20230613A1 (es)
TW (1) TW202216999A (es)
WO (1) WO2021260197A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115851725A (zh) * 2022-10-28 2023-03-28 珠海市人民医院 一种抑制解螺旋酶Ⅴ基因表达的siRNA及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
NZ503765A (en) 1997-09-12 2002-04-26 Exiqon As Bi-cyclic and tri-cyclic nucleotide analogues
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
CA2372085C (en) 1999-05-04 2009-10-27 Exiqon A/S L-ribo-lna analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
AU2003264441A1 (en) 2002-09-17 2004-04-08 The Circle For The Promotion Of Science And Engineering Method of screening remedy for proliferative disease
CA2994089A1 (en) 2002-11-18 2004-06-03 Roche Innovation Center Copenhagen A/S Antisense gapmer oligonucleotides
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
EP1984381B1 (en) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
ATE538127T1 (de) 2007-07-05 2012-01-15 Isis Pharmaceuticals Inc 6-disubstituierte bicyclische nukleinsäureanaloga
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
BR112013026423A2 (pt) 2011-04-20 2016-11-29 Roche Glycart Ag método e construtos para a passagem de pendente do ph da barreira sangue-cérebro
EP4269584A3 (en) 2011-08-11 2024-03-27 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
CA2889596C (en) 2012-11-15 2022-08-23 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
CN105378085B (zh) 2013-05-01 2019-02-15 Ionis制药公司 用于调节hbv和ttr表达的组合物和方法
CA2915316C (en) 2013-06-27 2024-01-02 Roche Innovation Center Copenhagen A/S Antisense oligomers and conjugates targeting pcsk9
CA2935426C (en) 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
US20170327524A1 (en) 2014-10-10 2017-11-16 Hoffmann-La Roche, Inc. Galnac phosphoramidites, nucleic acid conjugates thereof and their use
WO2016127002A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
KR102468177B1 (ko) 2016-04-14 2022-11-16 에프. 호프만-라 로슈 아게 트리틸-모노-GalNAc 화합물 및 이의 용도
CN112055749A (zh) 2018-04-05 2020-12-08 豪夫迈·罗氏有限公司 Fubp1抑制剂用于治疗乙型肝炎病毒感染的用途

Also Published As

Publication number Publication date
AU2021295609A1 (en) 2023-01-19
CR20220645A (es) 2023-02-17
MX2022016280A (es) 2023-02-09
CO2023000116A2 (es) 2023-03-27
CA3186722A1 (en) 2021-12-30
CN116033908A (zh) 2023-04-28
US20220031730A1 (en) 2022-02-03
BR112022026612A2 (pt) 2023-01-24
EP4171575A1 (en) 2023-05-03
IL299269A (en) 2023-02-01
TW202216999A (zh) 2022-05-01
WO2021260197A1 (en) 2021-12-30
JP2023531249A (ja) 2023-07-21
PE20230613A1 (es) 2023-04-13
KR20230028475A (ko) 2023-02-28

Similar Documents

Publication Publication Date Title
BR112019002117A2 (pt) agente de rnai contra infecção do vírus da hepatite b
BR112018068410A2 (pt) oligonucleotídeos para redução da expressão de pd-l1
BR112022012625A2 (pt) Compostos moduladores de diacilglicerol quinase
PE20190443A1 (es) Moleculas de acido nucleico para la reduccion de arnm de papd5 o papd7 para tratar la infeccion por hepatitis b
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
CL2020002563A1 (es) Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CO2023000116A2 (es) Oligonucleótidos mejorados para modular la expresión de fubp1
MX2020003464A (es) Molecula de acidos nucleicos para la reduccion del arnm de papd5 y papd7 en el tratamiento de la infeccion de la hepatitis b.
CU23794B7 (es) Inhibidores macrocíclicos de la replicación del virus de la hepatitis c
BRPI0906710B8 (pt) peptídeo derivado de pres modificado hidrofóbico de vírus da hepatite b (hbv) , peptídeo e composição farmacêutica
AR114551A1 (es) COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO
BR112023020781A2 (pt) Moduladores de cbl-b e usos dos mesmos
CL2021000018A1 (es) Oligonucleótidos para modular la expresión de rtel1
CL2020001638A1 (es) Molécula de ácidos nucleicos para la reducción del arnm de papd5 y papd7 en el tratamiento de la infección de la hepatitis b. (divisional solicitud 202000945)
AR113771A1 (es) Molécula de ácidos nucleicos para la reducción del arnm de papd5 y papd7 en el tratamiento de la infección de la hepatitis b
CL2022002980A1 (es) Conjugado de proteínas novedoso, y uso del mismo para prevenir o tratar esteatohepatitis no alcohólica, obesidad y diabetes
AR120817A1 (es) Oligonucleótidos mejorados para inhibir la expresión de scn9a
CL2022001340A1 (es) Oligonucleótido antisentido. conjugado de oligonucleótido antisentido.composición farmacéutica.divisional de solicitud 2018-02570
JO3769B1 (ar) علاج RNAi لعدوى فيروس التهاب الكبد B
CL2021003099A1 (es) Inhibidores tricíclicos del virus de la hepatitis b oxalamido-substituidos.
WO2021122921A8 (en) Use of cops3 inhibitors for treating hepatitis b virus infection